SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: 8-K
Document Type: EX-4.1
Date Filed: 2026-03-25
Accession Number: 0001213900-26-034072
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390026034072/ea028322301ex4-1.htm

Chunk 1 of 3
Word Count: 1483
Character Count: 9018

Document Content:

Company will not, by amendment of its Certificate of Incorporation or Bylaws or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and conditions and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the Holder against impairment. Fractional Shares. No fractional shares of Warrant Stock will be issued in connection with any exercise hereunder. In lieu of any fractional shares that would otherwise be issuable, the Company shall pay cash equal to the product of such fraction multiplied by the fair market value of one share of Warrant Stock on the date of exercise.

Stockholder Rights. This Warrant as such shall not entitle its holder to any of the rights of a stockholder of the Company until
the holder has exercised this Warrant in accordance with Section 6 or Section 7 hereof.

5. Company
Representations and Covenants. The Company represents and warrants to the Holder that this Warrant is duly authorized, validly issued,
fully paid and non-assessable with respect to the issue thereof. The Company covenants that during the period this Warrant is exercisable,
the Company will take all actions necessary to reserve from its authorized and unissued common stock a sufficient number of shares to
provide for the issuance of Warrant Stock upon the exercise of this Warrant, free from preemptive rights or any other contingent purchase
rights. The Company agrees that its issuance of this Warrant shall constitute full authority to its officers who are charged with the
duty of executing stock certificates to execute and issue the necessary certificates for shares of Warrant Stock upon the exercise of
this Warrant. The Company further covenants that it will not, without the prior written consent of the Holder, take any actions to increase
the par value of the Common Stock at any time while this Warrant is outstanding.

6. Exercise
of Warrant; Holder’s Exercise Limitations; Stockholder Warrant Approval.

Exercise. After a Qualified Event of Default, this Warrant may be exercised by Holder, in whole or in part, at any time or from
time to time, by the surrender of this Warrant at the principal office of the Company, accompanied by payment in full of the purchase
price of the shares purchased thereby, as described above. This Warrant shall be deemed to have been exercised immediately prior to the
close of business on the date of its surrender for exercise as provided above, and the person or entity entitled to receive the shares
or other securities issuable upon such exercise shall be treated for all purposes as the holder of such shares of record as of the close
of business on such date. As promptly as practicable, the Company shall cause its transfer agent to issue and deliver to the person or
entity entitled to receive the same shares equal to the number of full shares of Warrant Stock issuable upon such exercise, together
with cash in lieu of any fraction of a share as provided above. The shares of Warrant Stock issuable upon exercise hereof shall, upon
their issuance, be fully paid and nonassessable. If this Warrant shall be exercised in part only, the Company shall, at the time of delivery
of the Shares or other securities in respect of which this Warrant has been exercised, deliver to the Holder a new Warrant evidencing
the right to purchase the remaining Shares or other securities purchasable under this Warrant, which new warrant shall, in all other
respects, be identical to this Warrant. The Company shall take all actions as may be necessary to ensure that the Warrant Stock issuable
upon exercise of this Warrant is issued without violation by the Company of its organizational documents, any applicable law or governmental
regulations. The Company shall pay all expenses in connection with, and all taxes (excluding taxes based on income) and other governmental
charges that may be imposed with respect to, the issuance or delivery of the Warrant Stock upon exercise of this Warrant. If an exercise
by Holder is for less than all of the Warrant Stock purchasable under this Warrant, the Company will as soon as reasonably practicable
deliver to Holder a new Warrant or Warrants of like tenor, for the balance of the Warrant Stock purchasable hereunder.

6.2 Holder’s
Exercise Limitations. Until and unless Stockholder Warrant Approval is obtained, the Company shall not issue shares of Common
Stock issuable upon exercise of this Warrant to the extent that after giving effect to such issuance after exercise, the Holder
(together with the Holder’s affiliates, and any other persons acting as a group together with the Holder or any of the
Holder’s affiliates), would beneficially own in excess of 19.9% of the number of shares of the Common Stock outstanding
immediately after giving effect to the applicable issuance of shares of Common Stock issuable upon such exercise of this Warrant
(calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder) (the
“Beneficial Ownership
Limitation”). For purposes of the foregoing sentence, the number of shares of Common
Stock beneficially owned by the Holder and its affiliates shall include the number of shares of Common Stock issuable upon exercise
of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which
would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any
of its affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company
(including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to
the limitation contained herein beneficially owned by the Holder or any of its affiliates. Upon the written or oral request of a
Holder, the Company shall within one (1) business day confirm orally and in writing to the Holder the number of shares of Common
Stock then outstanding. If on any attempted exercise of this Warrant, the issuance of Warrant Stock would exceed the amount of
shares of Common Stock permitted by this Section 6.2, then the Company shall issue to Holder such number of Warrant Stock as may be
issued pursuant to this Section 6.2. The limitations contained in this paragraph shall apply to a successor holder of this
Warrant.

Stockholder Warrant Approval. The Company covenants to seek stockholder approval of the exercise of this Warrant for any amount
in excess of the Beneficial Ownership Limitation (the “Stockholder
Warrant Approval”) at the next annual meeting of stockholders, which shall be held no later
than June 30, 2026. The Company shall seek the Stockholder Warrant Approval in accordance with applicable law, the rules and regulations
of the NASDAQ Stock Market, the Company’s certificate of incorporation and bylaws and Chapter 78 of the Nevada Revised Statutes,
and the Company shall use its reasonable best efforts to solicit the Stockholder Warrant Approval and to cause the board of directors
of the Company to recommend to the Company stockholders that they approve the Stockholder Warrant Approval.

7. Net
Issue Election.

7.1. Right
to Convert. In addition to and without limiting the rights of the Holder under the terms of this Warrant, after a Qualified Event
of Default, the Holder shall have the right to convert this Warrant or any portion hereof (the “Conversion
Right”) into shares of Warrant Stock as provided in this Section 7. Upon exercise of the
Conversion Right with respect to a particular number of shares subject to this Warrant (the “Converted Warrant Shares”),
the Company shall deliver to the Holder (without payment by the Holder of any cash or other consideration) that number of shares of Warrant
Stock equal to the quotient obtained by dividing (x) the value of this Warrant (or the specified portion hereof) on the Conversion Date
(as defined in subsection 7.2 hereof), which value shall be determined by subtracting (A) the aggregate Warrant Price of the Converted
Warrant Shares immediately prior to the exercise of the Conversion Right from (B) the aggregate Market Price of the Converted Warrant
Shares issuable upon exercise of this Warrant (or the specified portion hereof) on the Conversion Date by (y) the Market Price of one
share of Warrant Stock on the Conversion Date. No fractional shares shall be issuable upon exercise of the Conversion Right, and if the
number of shares to be issued determined in accordance with the foregoing formula is other than a whole number, the Company shall pay
to the Holder an amount in cash in lieu of such fractional share as set forth in Section 3.